These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 29866007

  • 1. An Update on MDMX and Dual MDM2/X Inhibitors.
    Espadinha M, Barcherini V, Lopes EA, Santos MMM.
    Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
    [Abstract] [Full Text] [Related]

  • 2. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A, Leão M, Soares J, Palmeira A, Pinto M, Saraiva L, Sousa ME.
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [Abstract] [Full Text] [Related]

  • 3. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.
    J Hematol Oncol; 2017 Jul 03; 10(1):133. PubMed ID: 28673313
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
    Golestanian S, Sharifi A, Popowicz GM, Azizian H, Foroumadi A, Szwagierczak A, Holak TA, Amanlou M.
    Life Sci; 2016 Jan 15; 145():240-6. PubMed ID: 26746660
    [Abstract] [Full Text] [Related]

  • 5. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J, Wang SM.
    Int J Oncol; 2013 Dec 15; 43(6):1935-42. PubMed ID: 24126697
    [Abstract] [Full Text] [Related]

  • 6. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B, Gilkes DM, Chen J.
    Cancer Res; 2007 Sep 15; 67(18):8810-7. PubMed ID: 17875722
    [Abstract] [Full Text] [Related]

  • 7. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L.
    Mol Oncol; 2017 Jun 15; 11(6):612-627. PubMed ID: 28296148
    [Abstract] [Full Text] [Related]

  • 8. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N.
    Bioorg Med Chem Lett; 2013 Jul 01; 23(13):3802-5. PubMed ID: 23726030
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
    Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR.
    Chem Biol Drug Des; 2015 Aug 01; 86(2):180-9. PubMed ID: 25388787
    [Abstract] [Full Text] [Related]

  • 13. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.
    Cell Cycle; 2008 Jun 01; 7(11):1604-12. PubMed ID: 18520179
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MDM2/MDMX inhibitor peptide: WO2008106507.
    Macchiarulo A, Pellicciari R.
    Expert Opin Ther Pat; 2009 May 01; 19(5):721-6. PubMed ID: 19441944
    [Abstract] [Full Text] [Related]

  • 16. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA.
    Cell Cycle; 2007 Oct 01; 6(19):2386-92. PubMed ID: 17938582
    [Abstract] [Full Text] [Related]

  • 17. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
    Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS, Gao L, Tovar C, Lovey A, Wanner J, Vassilev LT.
    Proc Natl Acad Sci U S A; 2012 Jul 17; 109(29):11788-93. PubMed ID: 22745160
    [Abstract] [Full Text] [Related]

  • 18. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K, Mane J, Friesen D, Tuszynski J.
    J Mol Graph Model; 2010 Feb 26; 28(6):555-68. PubMed ID: 20056466
    [Abstract] [Full Text] [Related]

  • 19. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C, Pazgier M, Li C, Yuan W, Liu M, Wei G, Lu WY, Lu W.
    J Mol Biol; 2010 Apr 30; 398(2):200-13. PubMed ID: 20226197
    [Abstract] [Full Text] [Related]

  • 20. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O, Taylor N, Prutsch N, Staber PB, Moriggl R, Turner SD, Kenner L.
    Mutat Res Rev Mutat Res; 2017 Jul 30; 773():1-13. PubMed ID: 28927521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.